Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $6.3 million.

  • Syndax Pharmaceuticals' Cash from Financing Activities rose 10264.69% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $355.2 million, marking a year-over-year increase of 3432.32%. This contributed to the annual value of $353.4 million for FY2024, which is 3378.42% up from last year.
  • Syndax Pharmaceuticals' Cash from Financing Activities amounted to $6.3 million in Q3 2025, which was up 10264.69% from $551000.0 recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Cash from Financing Activities registered a high of $347.4 million during Q4 2024, and its lowest value of -$13.5 million during Q3 2022.
  • Over the past 5 years, Syndax Pharmaceuticals' median Cash from Financing Activities value was $2.2 million (recorded in 2024), while the average stood at $48.2 million.
  • Per our database at Business Quant, Syndax Pharmaceuticals' Cash from Financing Activities plummeted by 89325.51% in 2022 and then skyrocketed by 34416.52% in 2023.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Cash from Financing Activities stood at $109.8 million in 2021, then skyrocketed by 48.94% to $163.5 million in 2022, then soared by 58.09% to $258.5 million in 2023, then soared by 34.41% to $347.4 million in 2024, then crashed by 98.19% to $6.3 million in 2025.
  • Its Cash from Financing Activities was $6.3 million in Q3 2025, compared to $551000.0 in Q2 2025 and $930000.0 in Q1 2025.